America put me out of business homepage
1465  days in business since  challenge
3168  days dispensing drugs to  the us
Don't let drug companies like Pfizer put me Daren Jorgenson out of business by continuing to cut off supply to our pharmacies around the world if we sell their products to Americans. I want you to put me out of business by forcing these drug companies to sell their products to American Pharmacies at fair and reasonable prices.Daren Jorgenson Bsc PharmI want Americans to put me out of business the right way!
CanadaMeds.comAmerican Drug ClubCanadaRx.com
DAILY NEWS ARTICLES
WEEKLY NEWS ARTICLE
WEEKLY POLITICAL COMMENTS
DAILY POLITICAL NEWS ARTICLES
Political Supporters of Drug re-importation
JOHN KERRY SPEAKS

Click here to view Darens message to the American people.
MICHAEL MOORE COMMENTARIES
Toll Free
1-877-855-6995

Fax
1-877-855-6996
SIGN UP FOR OUR DAILY NEWSLETTER
Is Legalizing the purchase of prescription drugs from Canada the Answer?
 

Watchdog group eyes drug industry's political spending

Posted At WRAL.com

By: Associated Press

WASHINGTON -- The pharmaceutical industry's run of success on Capitol Hill has benefited from the more than $800 million spent since 1998 on lobbyists and political campaigns, a political watchdog group said Wednesday.

The trade group representing drug makers said the money helped patients.

In the past year, the industry hired nearly 1,300 lobbyists, including dozens of former lawmakers and hundreds of people who worked for congressional committees or regulatory agencies.

"It is astonishing to learn that no other interest has spent more money to sway public policy in this time period," said Roberta Baskin, the executive director of the Center for Public Integrity. The nonpartisan research group investigated the pharmaceutical industry's spending.

Baskin described the industry's motives for its spending as profit-driven.

Ken Johnson, senior vice president for the Pharmaceutical Research and Manufacturers of America, said the report was "clearly biased and one-sided."

He said it failed to acknowledge that "medicines researched and developed by America's biopharmaceutical research companies save lives and improve the quality of life for tens of millions of patients from around the world."

The center noted that the industry spent about $116 million on lobbying and political campaigns in 2003, which was the year Congress approved a new prescription drug benefit under Medicare.

In the same legislation, drug makers fought back attempts by Democrats that would have allowed the government to negotiate drug prices on behalf of beneficiaries.

Last year, according to the center, the industry spent $128 million on such efforts, including seeking tax breaks as part of a massive corporate tax relief bill.

Drug companies lobbied for $5.6 billion in spending for biodefense and for a bill that allows easier access to patents for inventions researched jointly by public institutions and private entrepreneurs.

Much of the data for the center's report comes from lobbying disclosure forms filed with the Senate. More than 3,000 people over the past seven years have done lobbying work for a pharmaceutical company.

The list includes former Sens. Bob Dole and Lloyd Bentsen and former Reps. Robert Livingston and Tom Foley, the center said.

Overall, 75 former lawmakers are listed as serving as lobbyists for a drug company since 1998. The industry's trade group hired former Rep. Billy Tauzin, R-La., as its president in December.

The industry is not happy with legislation that Senate Majority Leader Bill Frist said he will introduce that calls for a two-year ban on consumer advertising for new drugs. Nor are drug companies pleased by a proposal from the administration and governors that would reduce how much Medicaid pays for prescription drugs.


ARTICLES OF THE DAY

Bill to allow pharmacies to reimport drugs passes Senate

The Oklahoma Senate backs a drug reimportation plan that would permit state pharmacies to obtain U-S-made prescription drugs from Canada and elsewhere for sale here.The Federal Drug Administration has opposed drug reimportation bills, claiming they violate the Interstate Commerce Clause of the U-S Constitution. Those measures mainly deal with allowing individuals to obtain reimported drugs. Tulsa state Senator Tom Adelson says his legislation avoids that legal question because it would require pharmacies to sell reimported medicines only to Oklahomans in intrastate, not interstate, commerce. Most programs are geared to allowing individuals obtain such drugs by crossing the border into Canada or buying drugs online.

March 08, 2006

Democrats allege bad deal on drugs

Bay Area seniors are not saving significant money under Medicare's new prescription drug program, according to a report released Monday by most of the Bay Area's House Democrats. The report says Bay Area prices for 2004's 10 best-selling prescription drugs among seniors are 75 percent higher under the new Medicare Part D prescription drug benefit than under deals negotiated by the federal government at other agencies such as the Department of Veterans Affairs. Medicare Part D's prices also are 60 percent higher than those paid by consumers in Canada; almost 5 percent higher than prices on Drugstore.com; and almost 2 percent higher than prices at Costco, the report found. But Republicans who shepherded the bill through Congress rejected a proposal to let Medicare negotiate with drug companies for lower prices. The report proves "what we've been saying since the debate on the Republican Medicare drug bill began," said Rep. Pete Stark, D-Fremont, in a news release. "If you create a privatized drug benefit and refuse to let the government negotiate lower prices, senior citizens and people with disabilities will pay the price," said Stark, who as ranking Democrat on the House Ways and Means Committee's Health Subcommittee is particularly outspoken on the issue. "Instead of attempting to set Medicare on the road to privatization, Republicans in Congress should have worked with Democrats to establish a real prescription benefit within Medicare."

March 08, 2006